TCE1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetCelldex’s balance sheet shows very low debt and sizable equity, materially reducing solvency and refinancing risk for a capital-intensive biotech. This durable financial flexibility supports multi-year clinical programs and provides runway to fund R&D without immediate operating revenue.
Focused, Late‑stage Mast‑cell PipelineThe company’s concentrated pipeline—including two Phase 3 trials for barzolvolimab and a bispecific candidate CDX-622—represents a structural strength: late‑stage assets reduce development risk versus early programs and create a clear pathway to regulatory and commercial inflection points if trials succeed.
Governance Support And Incentive FlexibilityShareholder approval of an expanded equity incentive plan and re-election of directors signals board and investor alignment. The added authorization gives management a durable tool to retain talent and align incentives through lengthy development cycles, supporting execution continuity.
Bears Say
Accelerating Cash BurnOperating and free cash flows are persistently negative and have accelerated in the trailing twelve months, increasing funding pressure. This structural cash burn raises the probability of near-term financing needs and constrains the firm’s ability to self-fund pivotal trials without external capital.
Near‑zero And Deteriorating RevenueRevenue has fallen to near-zero on a TTM basis and remains volatile, reflecting no commercialized products. This structural lack of recurring revenue limits margin sustainability and forces reliance on non‑operating funding sources to support R&D and eventual commercialization investments.
Dependence On External Financing And Dilution RiskAs a clinical‑stage biotech with rising cash burn and minimal revenue, Celldex will likely rely on additional equity or partner funding. The recently expanded incentive share pool highlights potential dilution as an ongoing structural risk that can erode shareholder value if future financings are required.
Celldex News
TCE1 FAQ
What was Celldex Therapeutics Inc’s price range in the past 12 months?
Currently, no data Available
What is Celldex Therapeutics Inc’s market cap?
Celldex Therapeutics Inc’s market cap is CHF2.56B.
When is Celldex Therapeutics Inc’s upcoming earnings report date?
Celldex Therapeutics Inc’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Celldex Therapeutics Inc’s earnings last quarter?
Celldex Therapeutics Inc released its earnings results on Aug 06, 2026. The company reported -CHF0.763 earnings per share for the quarter, beating the consensus estimate of -CHF0.858 by CHF0.095.
Is Celldex Therapeutics Inc overvalued?
According to Wall Street analysts Celldex Therapeutics Inc’s price is currently Undervalued.
Does Celldex Therapeutics Inc pay dividends?
Celldex Therapeutics Inc does not currently pay dividends.
What is Celldex Therapeutics Inc’s EPS estimate?
Celldex Therapeutics Inc’s EPS estimate is -0.82.
How many shares outstanding does Celldex Therapeutics Inc have?
Currently, no data Available
What happened to Celldex Therapeutics Inc’s price movement after its last earnings report?
Celldex Therapeutics Inc reported an EPS of -CHF0.763 in its last earnings report, beating expectations of -CHF0.858. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Celldex Therapeutics Inc?
Currently, no hedge funds are holding shares in CH:TCE1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celldex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF47.11 (― Upside)
CHF47.11 (― Upside)
Blogger Sentiment
Bullish
CH:TCE1 Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.99%
Trailing 12-Months
Company Description
Celldex Therapeutics Inc
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
TCE1 Stock 12 Month Forecast
Average Price Target
―Nektar Therapeutics
―
Iovance Biotherapeutics
―
Nurix Therapeutics
―
Nuvation Bio
―
Immunome
―